2 Stocks to Buy Hand Over Fist in October
Axe Cap view
Two Healthcare Stocks Worth Watching This October
Nutex Health and Elevance Health offer compelling growth and value despite their strong recent performance.
Nutex Health, though little-known and small, stands out with eye-popping earnings growth—its EPS jumped nearly 28 times year-on-year. It trades at a modest 9 times trailing earnings, far cheaper than the sector average of almost 30. Regulatory shifts helping hospitals get paid more reliably add to its appeal. While Nutex’s small size means volatility risk and less analyst coverage, it’s exactly that ‘off-radar’ trait which could provide a compelling return if momentum continues. Elevance Health, a heavyweight insurer, looks steady and undervalued, trading at a forward price/earnings (P/E) ratio below its five-year norm. Its 15 years of dividend hikes hint at management confidence, and double-digit earnings growth expected in the next couple of years isn’t trivial. South Africans won’t find direct exposure here on the JSE, so watching USD/ZAR makes sense as the dollar strength impacts these offshore plays. Our view may misfire if regulatory headwinds worsen or macroeconomic shifts hurt U.S. healthcare demand. this is just our opinion and not financial advice
We’d watch Nutex for a buy opportunity ahead of broader analyst coverage, and consider Elevance for steady dividend income and growth, hedging exposure through the USD/ZAR rate. Avoid rushing in without monitoring regulatory updates.
- NUTX
- ELV
- USD/ZAR
- Regulatory changes in U.S. healthcare
- USD strength reversing unexpectedly
5/10
Nutex Health and Elevance Health are recommended as undervalued healthcare stocks despite strong year-to-date performance. Nutex, a small-cap hospital operator, trades at less than 9x trailing earnings with exceptional EPS growth of 2,785% year-over-year. Elevance, a major health insurer, trades at a forward P/E of 14.52 below its five-year average, with consistent dividend increases and strong earnings guidance for 2026-2027.
Our take is based on reporting first published by The Motley Fool.